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Osteoarthritis (OA) is currently an incurable and progressive condition in dogs causing
chronic joint pain and possibly increasing disability. Due to the poor healing capacity of
cartilage lesions that occur with OA, development of effective therapeutics is difficult.
For this reason, current OA therapy is mostly limited to the management of pain and
inflammation, but not directed ad disease modification. In the search for a safe and
effective OA treatment, mesenchymal stem cells (MSCs) have been of great interest since
these cells might be able to restore cartilage defects. The designs of OA studies on MSC
usage, however, are not always consistent and complete, which limits a clear evaluation
of MSC efficacy. The general study results show a tendency to improve lameness, joint
pain and range of motion in dogs suffering from naturally-occurring OA. Assessment of
the cartilage surface demonstrated the ability of MSCs to promote cartilage-like tissue
formation in artificially created cartilage defects. Immunomodulatory capacities of MSCs
also seem to play an important role in reducing pain and inflammation in dogs. It should
be mentioned, however, that in the current studies in literature there are specific design
limitations and further research is warranted to confirm these findings.
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OSTEOARTHRITIS
Characteristics of Osteoarthritis
Osteoarthritis (OA) is a commonly seen condition in veterinarymedicine, causing chronic pain and
increasing disability due to progressive joint degeneration (1–5). Prevalence studies described that
2.5% of dogs presented to primary practices in the UK with OA and more than 20% of dogs over
1 year old in the US are affected by OA (1, 3, 5). Specific breeds (e.g., Labrador, Golden Retriever),
castration, advanced age and obesity are suggested to be risk factors of OA development (1, 5, 6).
Although OA is often diagnosed in older dogs, it is not part of normal aging (4). Contrary
to human and feline OA, canine OA is in general secondary to trauma, including abnormal
loading on a normal joint (e.g., joint injury) or normal force on an abnormal joint (e.g.,
elbow and hip dysplasia) (1, 3, 4). Osteoarthritis is characterized by osteophyte formation,
bone remodeling, changes in peri-articular tissue and synovitis (2, 3). Nevertheless, the main
feature of OA is cartilage damage. When the cartilage homeostasis is disturbed, chondrocytes
become “activated” and produce inflammatory mediators which are able to stimulate progression
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of cartilage damage and adjacent joint tissue alterations,
establishing a vicious cycle of joint deterioration and worsening
OA (3, 7).
Unfortunately, due to relative avascularity and therefore the
lack of systemic regulation, the repair capacity of cartilage is
very poor (2, 3). For this reason, OA is a life-long progressive
disease that currently cannot be cured (4). The lack of an OA
cure necessitates management to reduce pain and inflammation,
to restore normal cartilage and joint function and to prevent
further damage (2). Many therapeutics are available which all
target different aspects of OA.
Osteoarthritis Management
Pharmacologic analgesia is probably the most common
component of OA management. Non-steroidal anti-
inflammatory drugs (NSAIDs), tramadol and gabapentin
are frequently used to reduce the pain and inflammation.
However, a profound patient selection and follow-up is indicated
since potential side effects are well-known (4, 5). Intra-articular
(IA) administration of hyaluronic acid (HA) and platelet rich
plasma (PRP) are effective to improve joint pain and mobility
and to influence healing of bone, tendon, muscle and ligament,
respectively (5, 8–11). It is also described that PRP induces
chondrogenesis, is able to increase anti-inflammatory mediators
and decrease pro-inflammatory mediators (11). Although
effective to manage OA related complaints, HA and PRP are
not able to cure cartilage damage. Since cartilage protection is a
difficult task of OA management, various food supplementation
products, frequently based on chondroitin, glucosamine,
methylsulfonylmethane (MSM), glycosylated undenaturated
type II collagen and omega-3 fatty acids, were developed. These
nutraceuticals might act as “building blocks” of cartilage and
reducers of inflammation. (4, 5, 12, 13). Unfortunately, except
for undenaturated type II collagen and omega-3 fatty acids,
scientific evidence on supplement efficiency is scares (4, 12–15).
Alternative OA management includes physical rehabilitation
and body weight control. Physiotherapeutic modalities and
exercises reduce pain and improve movement and joint function
(4, 5). A reduction of body weight decreases joint loading and
the risk of joint injury (4–7, 12). Although this kind of OA
management is simple, good results can only be achieved with
owner compliance.
Abbreviations: AD-MSCs, adipose tissue-derived MSCs; BVF, bone volume
fraction; COX, cyclooxygenase; CT, computer tomography; ECM, extracellular
matrix; ePB-MSCs, equine peripheral blood derived mesenchymal stem cells;
EVs, extracellular vesicles; GAG, glycosaminoglycan; GFP, green fluorescent
protein; HA, hyaluronic acid; IA, intra-articular; IL, interleukin; iNOS, inducible
nitric oxide synthase; iPSCs, induced pluripotent stem cells; IFN, interferon; IV,
intravenous; MHC, major histocompatibility complex; MRI, magnetic resonance
imaging; MSCs, mesenchymal stem cells; MSM, methylsulfonylmethane; NO,
nitric oxide; NSAIDs, non-steroidal anti-inflammatory drugs; OA, osteoarthritis;
PARP, poly adenosine diphosphate–ribose polymerase; PCR, polymerase chain
reaction; PRP, platelet rich plasma; PVF, peak vertical force; ROM, range of
motion; RT, repeated treatment; SEM, scanning electron microscopy; SOX, sex-
determining region Y-related high mobility group-box; TENS, transcutaneous
electrical nerve stimulation; TNF, tumor necrotic factor; TGF- β1, transforming
growth factor-β1; US, ultrasound; VEGF, vascular endothelial growth factor; VI,
vertical impulse.
Upcoming Importance of Mesenchymal
Stem Cells in the Osteoarthritis Research
Field
Since current OA management has its limitations and is
not able to reverse cartilage damage, new and promising
research areas have been explored. Biological therapies based on
mesenchymal stem cells (MSCs) have become of great interest
in both human and veterinary OA research. In contrast to
embryonic stem cells, MSCs are derived from adult tissue (16).
Being unspecialized and able to differentiate into multiple cell
lineages, including chondrocytes, these adult stem cells have the
capacity to repopulate cartilage defects (2, 17). Reduction of
local and systemic inflammation can be enabled by the MSCs’
immunomodulatory capabilities (2, 18, 19). Furthermore, MSCs
apply paracrine signaling which stimulate local repair cells that
may contribute to cartilage healing (2, 18–20). MSCs have also
been shown to possess homing capacities, meaning they can
be recruited, both locally and systemically, to sites of tissue
injury (21).
In human research, study results strongly suggest that MSC
therapy is effective in relieving pain and improving joint function
in patients suffering from OA. Especially the effect on knee OA
has been investigated thoroughly (22–24). Moreover, since no
obvious adverse effects are described, MSC use in humans might
be a safe and effective alternative for current OA management
therapies (22, 23). In veterinary medicine, being humans’ closest
companions and susceptible to OA, dogs and horses have been
the main focus of MSC research. As in humanOA research, study
results are promising, providing evidence that MSC treatments
may be safe and effective (25, 26). However, both human and
veterinary studies focused on the efficacy and safety of MSCs as
an OA therapy, many features of MSCs are not yet completely
understood. A growing knowledge about MSC capabilities may
provide the solution for both human and veterinary patients
suffering from OA by slowing down disease progression or even
reversing the damage and restoring full function.
Varieties of Mesenchymal Stem Cells in
Veterinary Research
In mesenchymal stem cell research, three types of MSCs can
be differentiated: autologous, allogeneic and xenogeneic MSCs.
When a patient receives its own MSCs, these MSCs are
autologous. AllogeneicMSCs refer toMSCs derived from a donor
animal of the same species as the receiving animal. Application
of donor MSCs of a different species is called xenogeneic.
Autologous derived MSCs are preferably used in veterinary
studies since these cells are immunologically compatible with the
receiving patient (27). Also, use of autologous MSCs does not
involve donor animal harvesting and so does not imply ethical
issues (28, 29). Harvesting every single patient and producing
autologous MSCs, however, is a time consuming and challenging
task for most veterinary practices. For this reason, many research
groups investigated MSCs derived from donor animals as an
attractive alternative. Allogeneic and xenogeneic MSCs are
“ready to treat” whichmeans that they can be prepared and stored
in commercial quantities (30). In donor-derived MSC studies,
Frontiers in Veterinary Science | www.frontiersin.org 2 May 2021 | Volume 8 | Article 668881
Brondeel et al. Mesenchymal Stem Cell Canine Osteoarthritis
allogeneic MSCs are preferred since they are expected to have
higher donor-host compatibility than xenogeneic MSCs (30).
Nevertheless, some canine studies did investigate the application
of xenogeneic equine and porcine MSCs (31, 32). Additional
features of xenotransplantation are absence of canine-specific
transferable pathogens and a higher culture capacity of equine
compared to canine MSCs (19).
The possibility of allogeneic and even xenogeneic MSC
usage was clarified by several canine and equine studies which
described MSCs to be “immune privileged.” It is proposed that
this interesting MSC feature is the consequence of an absent
major histocompatibility complex (MHC) class II expression on
its cell surface (27, 33). An absent MHC class II expression
is favorable in allogeneic and xenogeneic circumstances since
these molecules initiate an antigen-specific immune response by
presenting extracellular pathogens to CD4+ T cells (34). More
recent studies, however, described that MHC class II could be
up-regulated in vitro when presenting the MSCs in inflammatory
environments making them recognizable for the host’s immune
system. For this reason, this needs to be assessed before clinical
use (27, 33). Others described the possibility of allogeneic and
xenogeneic usage to be a consequence of immunomodulatory
capabilities of MSCs which reduces the relevance of a cellular
immune response after potential MHC upregulation. In addition,
suppression of the host’s immunological reaction toward donor
MSCs might enable allo- and xenotransplantation (30).
To apply autologous, allogeneic or xenogeneic MSCs as a
therapeutic tool, cells need to be harvested from tissue and
cultured in laboratory conditions. In canine OA research, the
use of a variety of MSC sources is described, such as adipose
tissue (28, 32, 35–51), bone marrow (52–58), synovium (59),
dental pulp (60), fetal adnexa (61), umbilical cord (62, 63) and
peripheral blood (31). Currently, adipose tissue and bonemarrow
seem to be the most popular MSC sources. The popularity of
adipose tissue-derived MSCs (AD-MSCs) can be attributed to an
easy accessibility and expansion in culture (29, 64, 65).
The aim of the current review article is to provide a clear
overview of currently reported canine OA research on MSC
application, with a main focus on study execution, efficacy
and safety results. Special attention is given to the distinctive





Types of Canine Osteoarthritis Research
on Mesenchymal Stem Cells
Current canine OA research on auto-, allo-, and
xenotransplantation of MSCs, can be subdivided into two
study types (based on the study population) (Figure 1). The
first type and majority of canine OA studies include companion
animals suffering from naturally-occurring OA (Tables 1, 2,
3) (28, 31, 32, 35–50, 60–62). In studies of a second type, joint
damage is induced in purpose-bred dogs in order to investigate
the potential of MSCs to heal cartilage (Tables 4, 5) (51–59, 63).
Studies evaluating naturally-occurring OA have an advantage
over model-based studies since they evaluate the effect of MSCs
on a real world (field) condition (28, 31, 32, 35–50, 60–62).
Nevertheless, establishing natural OA studies often encounters
some difficulties. Since, in this type of study, the targeted
population consists of owned animals, patient recruitment is
challenging and study populations are often rather small (31, 32,
37, 40–42, 45, 49, 50, 60). Also, a control group is frequently
missing because owners want their dog to actually be treated
(32, 35, 37, 39, 43, 45, 60). Moreover, OA affected dogs often
have problems inmultiple joints and the severity of OA can differ,
which may complicate study outcome interpretation (62).
In studies based on OA models, cartilage or cranial cruciate
ligament defects are created surgically in joints of purpose-bred
dogs before MSC administration (51–59, 63). In some studies,
however, MSCs are administered during or immediately after
surgery, which might not adequately represent the effect on
chronic OA (52, 53, 56–58). Compared to studies with client
owned animals, model based studies can easily include control
groups and provide the opportunity to apply a wider variety
of research tools (e.g., histopathology) (32). Unfortunately,
to enable histo- and pathologic examinations, which are
essential for thorough safety assessment, animal sacrifice is
sometimes required.
Mesenchymal Stem Cell Administration in
Osteoarthritis Studies
Several administration routes have been investigated to
administer MSCs to an OA affected or a purpose-bred dog
(Figure 1). Mostly, MSCs are administrated directly into the
affected joint by an IA injection (28, 31, 32, 35–39, 41, 42, 44–
51, 54, 55, 59–63). However, since MSCs are known to have
homing capacities, some studies investigated the effectiveness of
other administration routes (21, 40, 43, 44) such as: intravenous
(IV) administration (43, 44) and administration via acupuncture
points (40). Systemic delivery may be advantageous since these
MSCs may evoke a greater interaction with the immune system
than local delivered MSCs (43, 66). MSCs seem to be able to
enhance white blood cell activity, differentiation and migration
to lesion sites (66). Although further research is indicated to
clarify the exact mode of action, such a systemic interaction
with the immune system may lead to reduced inflammation
at multiple affected joints in the body (43, 66). Moreover, IV
administration can make MSC based treatments more accessible
for primary practice. Acupuncture point administration might,
according to a study in rats and dogs, enhance blood flow and
increase the level of vascular endothelial growth factor (VEGF),
transforming growth factor (TGF)-β1 and nitric oxide (NO),
improving angiogenesis and arteriogenesis (40, 67). Other
studies described the deposition of MSCs into the joint using a
scaffold. Scaffolds are tissue-engineered constructs, consisting
of a distinct cartilage and bone layer, which can be transplanted
into large osteochondral defects to offer a template for new tissue
formation and organization. Prior to transplantation, MSCs are
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FIGURE 1 | Schematic overview of mesenchymal stem cell administration in canine osteoarthritis studies [Modified from Lo Monaco et al. (20)].
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hip fat IA 4.2–5 × 106 1 + No
Black et al., (35) 14 MSC: 14 elbow fat IA 3–5 × 106 1 + No
Guercio et al.,
(37)
4 MSC + HA: 2
MSC + PRP: 2
elbow fat IA 3–5 × 106 1 + No
Yoon et al., (50) 1 MSC + surgery +
HA: 1
stifle fat IA 1 × 106 1 + No
Vilar et al., (48) 13 MSC + PRP: 8
Control: 5
hip fat IA 15 × 106 1 + No
Cuervo et al., (36) 35 MSC: 18
PRP: 17
hip fat IA 30 × 106 1 + No
Nicpon et al., (42) 12 MSC: 8
Control: 4
elbow fat IA 1.5 × 106 1 + No
Vilar et al., (46) 15 MSC: 10
Control: 5







stifle fat IA 2–3 × 106 1 + No
Vilar et al., (47) 15 MSC: 10
Control: 5
hip fat IA 15 × 106 1 + No
Srzentic Drazilov
et al., (45)
10 MSC: 10 Different
joints
fat IA >15 × 106 1 + No
seeded on these scaffolds (52, 56, 57). Based on a matched-pair
study by Kim et al. (68), MSC administration on a scaffold was
more efficient to improve clinical and arthroscopic outcomes in
humans with stifle OA than MSC administration via IA injection
(68). However, since the wide variety of described scaffold types,
the finding of Kim et al. (68) should not be generalized.
In current OA research on MSCs, specific dose determination
and safety studies are currently lacking and so the amount of
MSCs and frequency of administration is very variable between
publications. Doses are often based on the knowledge and
experience of the authors, the applied tissue, the laboratory
conditions, the amount of passages and viable cells. In autologous
studies evaluating naturally-occurring OA, AD-MSCs dose
varied from 1× 106 to>15× 106 cells administered with a single
IA injection (28, 35–37, 41, 42, 45–48, 50). Doses of single and
repeated IA, IV and acupuncture point injections of allogeneic
MSC to OA affected dogs ranged from 0.2 × 106 cells to 2
× 106 cells per kilogram bodyweight (38–40, 43, 44, 49, 60–
62). In xenogeneic naturally-occurring OA studies, single IA
injections of 5 × 106 porcine MSCs in canine stifle joints (32)
and 1 × 106 equine MSCs in canine elbow joints (31) were
performed. In model-based autologous studies, the amount of
MSCs administered by a single IA injection or implantation
ranged from 5 × 105 to 5 × 107 cells (53, 55, 56, 58, 59). To
transfer the MSCs to the defect side in allogeneic studies, up to
5 x 107 MSCs were seeded on a scaffold (52, 57) and 1× 106 to 1
× 107 MSCs were injected IA (up to four injections) (51, 54, 63).
Within the field of MSC research, MSCs are often
characterized before administration. Next to the standard
measures such as cell count, viability, sterility and cell adhesion,
MSCs can be characterized using different cell surface markers,
trilineage differentiation and morphology characterization.
However, the majority of canine OA studies using MSCs
did not perform a complete characterization of their applied
cells. In most studies on naturally-occurring OA in dogs, at
least two of the earlier mentioned analysis/analyses of MSC
characteristics were lacking. The types of lacking analyses
differed greatly between studies, but in general cell morphology
and proliferation were the least evaluated MSC characteristics.
An analyzation of the cell surface markers was described
most commonly (28, 32, 35–50, 60–62). Daems et al. (31),
who investigated the use of xenogeneic MSCs in dogs with
naturally occurring OA, presented the most complete set of
MSC characterizing analyses (31). In canine model-based OA
studies on MSC usage, the lack of performed MSC characterizing
analyses was even more pronounced than in naturally-occurring
OA studies (51–59, 63). In most of these studies, only an
evaluation of cell adhesion and cell surface markers was
performed (51, 53, 54, 63). This insufficient evaluation of MSC
characteristics is an important limitation in current canine MSC
research, making proper data interpretation and comparison
challenging. To improve future studies, MSC characterizing
analyses need to become standardized.
Besides the MSCs, some research groups administrated
additional products and evaluated their possible MSC
potentiating effect in OA affected joints. Typically, the
additional products were HA (37, 39, 49, 50, 54, 58, 59) or
PRP (36, 37, 48, 51, 53). A comparison between the clinical
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effect of solo administration of additional products and MSCs
was, although interesting, only made by three research groups
(36, 54, 59).
Mesenchymal Stem Cell Efficacy
Evaluation in Osteoarthritis Studies
Evaluation of MSC efficacy as an OA therapy was conducted
by a wide array of research tools. In general, studies evaluating
naturally-occurring OA were evaluated orthopedically based on
lameness, pain at joint manipulation and/or range of motion
(ROM) (28, 31, 32, 35, 36, 38–42, 44, 45, 49, 60–62). Additionally,
assessment of the effect of anMSC treatment onOA affected dogs
may include owner questionnaires/evaluations (28, 31, 32, 35–
41, 43, 47, 60–62), medical imaging (31, 32, 36, 41, 42, 49, 60),
synovial fluid analyses (31, 41–43) and objective gait analysis
by force or pressure plate (31, 32, 43, 46–48, 62). In most
naturally-occurring OA studies, MSC safety was also assessed
(31, 32, 36, 38, 42, 43, 49, 61, 62). By using purpose-bred
dogs instead of client-owned dogs, model-based OA studies
allowed evaluation of MSC treatments with macroscopic and/or
microscopic joint assessments (51–59). Additional applied
research techniques/tools described in autologous and allogeneic
model-based studies were: lameness evaluations (51, 55), medical
imaging (54, 57, 63), biochemical evaluations (56), biomechanical
evaluations (51, 56, 57), micro-computer tomography (CT) (52,
56, 57), green fluorescent protein (GFP)-labeling for homing
assessment (55), real-time polymerase chain reaction (PCR) (51),
spectrophotometry (51), scanning electron microscopy (SEM)
(63) and blood analyses (63).
STUDY OUTCOMES
Lameness and Joint Function
Study outcomes based on lameness, pain at joint manipulation
and/or range of motion were favorable for all MSC types, sources
and administration routes, and in both naturally-occurring OA
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and model based studies (28, 31, 32, 35–42, 44–48, 50, 51, 55,
60–62). For example, after a single IA injection of autologous
adipose tissue-derived MSCs to 10 OA affected dogs, significant
improvement of lameness and ROM up to 4 years post-
treatment was described (45). Compared to IA administration,
studies on allogeneic adipose tissue-derived MSCs showed IV
administration to be clinically less satisfying (43, 44). In Australia,
allogeneic adipose tissue-derived MSCs have been commercially
available since 2010 as IA and IV treatmentsfor dogs suffering
from OA. Shah et al. (44) reported these treatment results
and showed a higher percentage of dogs to have a good to
excellent quality of life (based on pain, mobility and daily
activity) after IA or combined IA-IV treatment (∼90%) than
after IV treatment alone (76%) (44). Olsen et al. (43) reported
improvement of client-specific outcome measures, however,
objective outcome measures did not confirm these results (43).
One study on allogeneic adipose tissue-derived MSCs described
clinical improvement after acupuncture point injections in four
of five dogs suffering from hip OA (40). Addition of PRP and
HA to MSC treatments was reported to have a positive effect
on study outcomes (37, 39, 49, 50). Nevertheless, only one
study made a comparison of MSC treatment with and without
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additional product (49). Wits et al. showed a greater/earlier
improvement of lameness and pain at joint manipulation after
combined IA administration of allogeneic adipose tissue-derived
MSCs and HA than after solo IA administration of MSCs (49).
The difference in effect of additional or solo administration of
HA or PRP was addressed by three research groups. Two model
based studies describe a better cartilage repair after combined
IA administration of autologous synovium and allogeneic bone
marrow derived MSCs and HA than after HA alone (54, 59).
A study that investigated the joint function after a single IA
injection of autologous adipose tissue-derived MSCs and a
single IA injection of PRP found enhanced joint mobility and
functionality for both products. For these parameters, however,
the effect of PRP was less pronounced or did not last as long as
the effect of the MSCs (36).
Gait analyses based on force or pressure plate enables objective
evaluation of a dog’s lameness and limb function. Nevertheless,
only a few research facilities studying the effect of autologous,
allogeneic and xenogeneic MSCs evaluating naturally-occurring
OA were equipped with a force or pressure plate (31, 32,
43, 46–48). The objective gait evaluations, however, did not
always support clinical lameness exam outcomes. For example,
Vilar et al. (46, 47). demonstrated significant improvement
of mean peak vertical force (PVF) and vertical impulse (VI)
values within the first 3 months after solo IA adipose tissue-
derived MSC treatment (46, 47). Despite subjective assessment
showing improvement, the dogs returned to the initial lameness
state 6 months post-treatment (47). Others did not report any
significant change in gait evaluation (31, 32, 43, 62). One study
on autologous adipose tissue-derived MSCs reported a reduced
lameness based on force plate analyses after a combined MSC
and PRP administration (48). Compared to similar studies
of the same research group only using MSCs, addition of
PRP seems to enable a more long-lasting lameness reduction
(46–48).
MSC treatments seem to have a favorable clinical effect on
lameness, joint pain and ROM. Although IA administration
appears to be most promising, careful data interpretation
is indicated since clinical lameness results are not always
supported by objective gait analysis. Additional administration
of HA and PRP may improve both clinical and pressure/force
plate outcomes.
Osteoarthritis Progression
None of the studies on autologous and allogeneic MSC
in dogs with naturally-occurring OA involving radiographic
and CT imaging did show improvement of superficial bone
changes 3 – 12 months post-treatment (36, 41, 42, 49, 60).
Nevertheless, throughout the study period, no radiographic OA
progression was detected after IA application of autologous and
allogeneic adipose tissue-derived MSCs (41, 49). In contrast,
a study applying autologous adipose tissue-derived MSCs in
combination with HA and patellar luxation surgery described
a decrease in osteophytes and subchondral cystic lesions on
radiographic evaluation (50).
Based on radiographic and CT imaging, it was concluded
that therapeutically administered MSCs are probably unable
to reverse OA-related superficial bone changes, however, they
may be able to slow down or even stop OA progression.
Additionally, it is important to realize that bone remodeling and
thus radiographic changes take time, which might have been the
limiting factor of some of these studies.
Cartilage and Subchondral Bone
Evaluation and Properties
The presence of newly formed cartilage was visualized by
macroscopic, microscopic and arthroscopic assessment and
by MRI and SEM screening. In several model based studies
evaluating autologous or allogeneic MSC usage, macroscopic and
histologic evaluations, conducted between 8 and 24 weeks after
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MSC treatment, showed that experimentally created cartilage
defects were (partially) filled with cartilage-like tissue, while the
defects of the control groups were filled with fibrous tissue
(52–56, 58, 59). An arthroscopic evaluation and biopsy of an
natural occurring OA defect showed cartilage regeneration 12
months after combined IA administration of allogeneic adipose
tissue-derived MSCs and HA (39). In model-based studies on
IA administration of allogeneic umbilical cord-derived and
bone marrow-derived MSCs, respectively joint repair after 28
days and the presence of cartilage-like tissue after 28 weeks
were reported based on MRI screening (54, 63). Li et al. (54)
described cartilage-like tissue to be present after combined
administration of MSCs and HA and after administration of
HA alone, however, the cartilage-like tissue was thicker after
the combined administration (54). To obtain a highly detailed
presentation of the cartilage surface, SEM was applied by a
model-based study on allogeneic umbilical cord-derived MSC
usage. In the treated group, which was IA injected with MSCs,
some small protuberances of cartilage on the articular surface
were present 35 days post-treatment. The thickness of the new
cartilage in the treated group was significantly higher than the
thickness of the cartilage in the control group (63).
Cartilage production was assessed by a research group
evaluating allogeneic transplantation of adipose tissue-derived
MSCs in a cranial cruciate ligament transection study. The
research group analyzed immunoreactivity against BrdU, a
cell proliferating marker. The number of BrdU-positive cells,
proliferating chondrocytes, was significantly decreased in the
control group and significantly increased in the treatment
groups. The increase of cell proliferation was most significant
after a combined treatment of MSCs and PRP (51). Additionally,
an immunohistochemistry test against caspase-3 and poly
adenosine diphosphate–ribose polymerase (PARP), which play
a role in cell apoptosis and death, respectively, was conducted.
The test results showed an increase of caspase-3- and PARP-
positive cells in OA conditions and a decrease after MSC and/or
PRP administration (51). Evaluations based on real-time PCR
demonstrated an increase of extracellular matrix (ECM)-related
genes (cartilage aggrecan and sex-determining region Y-related
high mobility group-box [SOX]9) in the groups treated with
MSCs, PRP or a combination. The increase of ECM-related genes
was most prominent after the combination treatment (51).
The content of collagen and glycosaminocglycan (GAG),
important components of hyaline cartilage, were evaluated
by biochemical, spectrophotometric and immunochemical
analyses. Biochemical evaluations performed by a research
group evaluating autologous bone marrow-derived MSCs in OA
models, demonstrated the GAG content of tissue-engineered
cartilage to be 84.82% 6 months after MSC enriched scaffold
implantation. This reported percentage approaches the GAG
content of normal cartilage in vivo (56). Spectrophotometric
analyses of the ECM were performed by a cranial cruciate
ligament transection study on allogeneic adipose tissue-derived
MSCs and showed the collagen and GAG content to be
significantly higher in the MSC treatment group than in the
control group (51). Immunochemical analyses conducted by a
model-based study on allogeneic bone marrow-derived MSC
usage demonstrated that type II collagen formation was present
in a group with MSC administration, but higher in another
group with combined MSC and HA administration. The study
suggested that combined usage of MSCs and HA could stimulate
the regeneration of cartilage better than HA alone (54).
In model-based studies on autologous or allogeneic bone
marrow-derived MSC application, implanting scaffolds in
osteochondral defects, subchondral bone was assessed by micro-
CT (52, 56, 57). Qiang et al. (56) showed regularly formedmature
trabecular bone 3 and 6 months after autologous MSC enriched
scaffold treatment. Between control and treatment group,
however, no significant differences onmicro-CT assessment were
found (56). On micro-CT evaluations of Duan et al. (52), large
quantities of spongy bone were seen in the pours of the scaffold,
both in the MSC enriched scaffold group and in the unseeded
scaffold group (52). In contrast, in the study of Qiang et al.
(57), micro-CT showed collapse of the high-load-bearing areas
of the femoral head. Furthermore, the bone volume fraction
(BVF) was lower in the treated than in the normal femoral
heads (57).
Biomechanical analyses of cartilage and subchondral bone
were conducted in model-based studies after autologous and
allogeneic MSC administration (51, 56, 57). Biomechanical
analyses applying autologous bone marrow-derived MSCs
tested the stiffness of cartilage and osteochondral bone
after MSC enriched scaffold implantation. 6 months after
treatment, cartilage stiffness was 70.77% of normal cartilage
and osteochondral bone stiffness was 74.95% of normal
osteochondral bone. Thus, the newly formed cartilage and
subchondral bone were only slightly softer than normal
osteochondral tissue (56). In an allogeneic transplantation study,
the focal compression strength of the affected articular surface
was, compared to the control, significantly higher 5 months after
administration of adipose tissue-derived MSCs and/or PRP. The
highest strength was seen in the group combining MSCs and
PRP (51). Reported stiffness of the high-load-bearing area of the
femoral head 3 and 6 months after allogeneic bone marrow-
derived MSC enriched scaffold treatment was only 57.3% of
normal stiffness. In this study, the scaffold failed to repair the
created osteochondral defects (57).
Although study protocols are very variable, according to visual
evaluations of the joint surface and assessments of cartilage
production, MSC administration seems to be sufficient to cover
chondral defects with cartilage-like tissue. The compositional and
biomechanical characteristics of this newly formed cartilage are
very similar to those of in vivo cartilage.
MSC Homing
MSC homing capacities were assessed by a model-based study
on autologous bone marrow-derived MSCs, which performed
a fluorescence analysis. GFP-labeled MSCs were detected in
neocartilage 2 and 8 weeks after IA injection and thus confirmed
MSC homing (55). These results are comparable to a similar
model-based study in donkeys assessing the homing capacity
of IA injected, GFP-labeled autologous bone marrow-derived
MSCs. Fluorescence microscopy assessment confirmed the
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incorporation of GFP-labeledMSCs in the newly formed cartilage
1, 2 and 6 months post-treatment (69).
In contrast, in a study on IV injection of allogeneic adipose
tissue-derived MSCs, MSCs labeled with a cell membrane
dye were rarely detected in the synovial fluid (43). In a
rabbit and horse study, however, homing of IV injected,
respectively, autologous and allogeneic MSCs to places of tissue
injury was confirmed (70, 71). Olsen et al. (43) reported
pulmonary trapping, to early assessment of the synovial fluid,
detainment in the synovial membrane and inadequate cell
labeling as possible causes of their insufficient MSC homing
detection (43).
Based on labeledMSCs detection studies, the principle ofMSC
homing after IA and IV administration seems to be promising
for OA affected animals. In dogs, however, there is a discrepancy
between study results after IA and IVMSC administration, which
is probably a consequence of MSC distance to injury location.
Otherwise, insufficient homing detection may be caused by
unfitted assessment procedures. To uncover assessment failures,
study results should be compared to clinical outcomes. For a
better understanding of MSC homing in dogs, further research
is warranted.
Inflammation Biomarkers and Synovial
Fluid Characteristics
Evaluations of synovial fluid were performed in naturally-
occurring OA studies (31, 41–43). A decrease of chronic
inflammation signs was detected 6 months after IA
administration of autologous adipose tissue-derived MSCs.
The numbers of leucocytes, neutrophils and mononuclear cells
were within normal ranges, as was the color and viscosity of
the synovial fluid (42). 12 months after autologous adipose
tissue-derived MSC administration, however, another study did
not detect significant synovial fluid changes (41). Also, after
repeated IV injection of allogeneic adipose tissue-derived MSCs,
no significant changes in OA biomarkers [prostaglandin E2
(PGE2) and matrix metalloproteinase-2 (MMP-2)] were found
(43). After IA administration of equine peripheral blood-derived
MSCs, analysis of synovial fluid, focusing on hemarthrosis
and viscosity, remained unchanged in dogs suffering from
naturally-occurring elbow OA (31).
Immunohistochemistry was applied in a cranial cruciate
ligament transection study on allogeneic transplantation of
adipose tissue-derived MSCs. Immunoreactivities in the cartilage
tissue were determined against pro-inflammatory cytokines,
tumor necrotic factor (TNF)-α, cyclooxygenase (COX)-2,
interleukin (IL)-1β, inducible nitric oxide synthase (iNOS)
and interferon (IFN)-γ, which significantly decreased in the
treatment group compared to the control group (51).
In a model-based study, blood analyses after IA allogeneic
umbilical cord-derived MSC treatment evaluated inflammatory
factors such as IL-6, IL-7 and TNF-α. No significant differences
were detected 3 and 28 days after MSC treatment. At day
seven, however, IL-6 and TNF-α were significantly higher in the
untreated group. At day fourteen, significantly lower levels of
IL-6, IL-7 and TNF-α were detected in the treated group (63).
According to blood analyses and immunoreactivity
evaluations of the cartilage surface, MSC administration
appears to decrease levels of inflammatory factors. Assessments
of synovial fluid, however, did not always show significant
changes. Evaluation of the effect of MSCs on joint inflammation
is challenging due to the variety of study designs and
assessment protocols. The applied MSC type, for example,
may influence study results. To better understand the effect of
MSC treatments on joint inflammation, further investigation
is indicated.
Safety
A safety assessment of IA and IV administration of MSCs
was performed in some naturally-occurring OA studies, but
important adverse events were not reported (31, 32, 36, 38, 42,
43, 49, 61, 62). Only a few minimal side effects were noted by
a minority of studies, such as worsening of lameness due to
injection difficulties (46), mild skin allergy (44) and self-limiting
joint distension (39, 61). Also, no MSC related negative effects
were reported in model-based studies (51–59, 63).
PROSPECTIVES AND CONSIDERATIONS
OF MSC BASED OA THERAPIES
Therapies based onMSCs seem to be promising for improvement
in joint function and to heal cartilage defects in OA affected dogs.
MSCs have the ability to forge a novel means to manage not
only the clinical impact of OA in dogs, but also to modulate the
disease. To overcome the practical difficulties of harvesting and
cultivating autologous MSCs, “ready to treat” products based on
allo- and xenotransplantation would be ideal for the practitioner.
Moreover, to facilitate MSC administration, systemic delivery
features are of researchers’ interest.
In recent literature, suggestions have been made about
other interesting stem cell related therapies besides MSC-
based therapies. Induced pluripotent stem cells (iPSCs) can be
obtained by reprogramming adult cells and have the ability
to differentiate into any cell type of the body. Compared
to MSCs, iPSCs have a greater differentiation potential and
might be able to provide a higher stem cell yield per donor.
However, iPSCs are described to be related to tumorigenesis,
thus making them less safe to use and unfitted as an MSC
alternative (72–74). To be able to consider iPSCs in future
medicine, additional studies addressing safety and efficacy
need to be performed. Alternative upcoming research has
been directed toward cell-free stem cell related therapies.
Cell-free stem cell related research focuses on the stem
cell’s paracrine factors, including extracellular vesicles (EVs),
which seem to play an important role in its effectiveness.
It is hypothesized that these EVs may be able to heal
and prevent tissue damage with a lesser impact on the
immune system. Nevertheless, before considering this MSC
alternative, more studies need to be conducted according to
mode of action, bioavailability and administration of EVs
(26, 74).
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CONCLUSION
In current canine medicine, a variety of MSC studies were
enrolled to encounter the problem of OA. These studies have
were very different based on study design, e.g., MSC sources,
MSC dosage, administration and efficacy evaluation. However, in
general, studies on auto-, allo-, and xenotransplantation of MSCs
show to be promising. Research assessing the effect of MSCs
on naturally occurring OA mostly demonstrated positive clinical
outcomes for all three transplantation types, e.g., a decrease
of lameness and joint pain and an increase of joint function.
The reported clinical signs were most significant after IA MSC
administration. In contrast, results based on medical imaging,
objective gait analysis and synovial fluid evaluations were more
doubtful. Addition of PRP or HA might be able to improve
treatment outcome compared to solo MSC administration. In
accordance with studies on naturally occurring OA, model-based
studies administering autologous or allogeneic MSCs described
reduced lameness and joint discomfort. Moreover, a variety of
research tools showed that the administration of MSCs, whether
or not on a scaffold, did induce the formation of cartilage-like
tissue. Both in naturally-occurring OA and model based studies,
the limited adverse events were minor, indicating that MSCs can
be applied safely in canine OA patients.
Although many promising results of MSC studies, careful
data interpretation is indicated since the reported study set-ups
are often very different which makes outcome evaluation and
comparison challenging. Also, naturally-occurring OA studies
are frequently lacking sufficient study populations and/or
control groups, depreciating reported findings. To overcome
these hurdles, standardization should be provided by future
development of evidence based protocols. Such protocols should
ensure strictly designed, blinded, randomized and controlled
studies applying well-characterized MSCs (i.e., determination of
cell viability, morphology, presence or absence of cell surface
markers, differentiation and population doubling times) at
considerable dosages. Moreover, further research investigating
mode of action and safety will attribute to a better understanding
of the possibilities of MSCs as an OA healing product.
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